OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 745 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... March 23, 2023 Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma December 10, 2025 An apple a day keeps the doctor away November 2, 2020 Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and... May 7, 2024 Load more HOT NEWS 41-Year-Old Wrinkled Woman Who Ages 8 Times Faster Than Normal Is... Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... EMA Recommends Granting a Marketing Authorisation for Poherdy Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer
